Copper Peptides Are Everywhere. Here's What the Regulators Actually Said.
A US advisory committee recommended six peptides for compounding this month, on votes as close as 8 to 6. Australia's regulator named copper peptide among unapproved products it is actively pursuing. Both happened in the same fortnight, and neither answers the question you actually have.
Dr. Alice Rudd and Joanne Wismeyer
Cofounders·30 July 2026·8 min read
A copper peptide serum sits on a shelf in a shopping centre. A vial of the same compound, ordered from an overseas website, sits in somebody's fridge.
The distance between those two things is shorter than it looks. This month, two regulators on opposite sides of the Pacific said very different things about the space in between.
What the FDA committee did, and what it did not do
On 23 and 24 July, the United States Food and Drug Administration's Pharmacy Compounding Advisory Committee considered seven peptides. It recommended six of them for possible inclusion on the 503A bulks list, the set of substances certain compounding pharmacies may prepare.
The headline travelling furthest since has been some version of peptides are legal now. That is not what happened.
The committee's recommendations are not binding. They add nothing to any list, approve no substance, and authorise no pharmacy to begin compounding anything. Adding a substance still requires a public rulemaking process.
The votes were also close, and the committee broke with the agency's own scientists to reach them. On BPC-157, KPV and TB-500 the split was eight in favour, six against, one abstention.
The dissenting reasons are the interesting part. One committee member, Dr Elizabeth Rebello, explained her vote against BPC-157 plainly: "I voted 'no' because of the lack of efficacy data. There were no [randomized controlled trials]."
A recommendation arrived at by eight votes to six, over the objection of the agency's own scientists, is not the same thing as evidence that something works.
One more detail matters for anyone reading this because of a serum. Copper peptide was not among the seven. The peptides considered were BPC-157, KPV, TB-500, MOTS-c, Semax, Epitalon and emideltide, the last being the only one the committee declined to recommend.
Australia is moving in the opposite direction
On 10 June 2026, the Therapeutic Goods Administration added unapproved peptide products to its compliance focus areas. It cited a joint operation with the Australian Border Force and Victoria Police that seized peptide products, performance and image enhancing drugs and illicit steroids, together valued above two million dollars.
On 19 June it went further and named examples, listing "products containing BPC-157, GHK-Cu, TB-500, retatrutide and CJC-1295" (TGA, 19 June 2026). GHK-Cu is the copper peptide.
The same statement reported serious adverse effects drawn from reports to the TGA and hospitalisation data from states and territories. Australia's Chief Medical Officer, Professor Michael Kidd, put it without hedging: Australians should not use these products.
Then on 20 July the TGA turned to the people selling them. Its notice covers "websites, online marketplaces, social media posts, influencer content and other forms of digital marketing", and states that influencers and affiliates may be held accountable for unlawful advertising (TGA, 20 July 2026).
Worth being precise about
The TGA is describing unapproved therapeutic goods — typically powders or injections in vials of uncertain origin, bought online or from overseas. A topical serum sold by an Australian retailer sits in a different regulatory category. It is not the thing the TGA named, and nothing here suggests otherwise.
Why people climb the ladder
The regulatory notices explain the risk well. They do not explain the behaviour, and the behaviour is the part worth understanding.
Consider the ordinary version of it. Somebody buys a copper peptide serum, uses it diligently for six weeks, and sees nothing they would swear to.
At that point there are two explanations, and from the inside they are indistinguishable. Either the product is doing nothing, or it is doing something too gradual to notice.
Without a record, you cannot separate them. And when you cannot separate them, the marketing has an answer waiting: the format was too weak.
Each rung of the ladder is a response to an information gap, not to evidence.
So it goes serum, then a stronger serum, then rolling it in with needles, then a vial from a website. Nobody decides to end up at the top. They arrive there one reasonable-seeming step at a time.
Content is shaped to fit that gap. A caption promising a result one hundred per cent of the time is unfalsifiable by design, because no observation you could make would ever contradict it.
How to judge a topical product fairly
The alternative to belief is not cynicism. It is a record.
To be clear about what follows
This applies to cosmetic products bought from a legitimate retailer. It is not a method for evaluating an unapproved peptide product, and it is not an argument for trying one. A skin record says nothing about whether something is sterile, correctly labelled or lawful to import, and no amount of self-tracking makes an unapproved product a reasonable thing to put in your body. Where the TGA has advised against a product, that advice stands regardless of what anyone measures.
Start the record before you start the product. One made four weeks in is not a starting point, it is a guess with a timestamp on it.
Change one thing at a time. If three products begin in the same fortnight, no outcome can be attributed to any of them.
Hold the conditions still. Same room, same time of day, same distance, no makeup — skin looks materially different under a bathroom downlight at 11pm than by a window at 8am.
Give it eight to twelve weeks, and read the trend rather than the day. Single readings move for reasons that have nothing to do with what you put on your face.
And decide in advance what would count as no. A test you cannot fail is not a test.
Where Stella fits
Stella scans your skin and keeps the readings, so the comparison is against a record rather than a memory.
A scan takes about thirty seconds. Do one before you next change your routine, leave everything else alone, and let the trend accumulate.
None of this settles whether copper peptides do anything for how your skin looks. That question is genuinely open, and anybody answering it with total confidence is selling something.
A record settles a narrower question, and a more useful one. For the products you are legitimately using, it tells you whether anything shifted over the weeks you used them — including the honest possibility that nothing did.
Which is the point. The ladder is climbed by people who cannot tell whether the last step changed anything, so the answer to it is not a stronger product. It is knowing where you stand before you take the first one.
Start your baseline →
One scan takes 30 seconds. No routine changes needed to begin, and nothing to decide today.
The information in this article is for educational purposes only. It is not medical advice, and nothing in it is a recommendation to use any peptide product. Stella is not a medical device and does not diagnose or treat any skin condition. If you have a skin concern, please consult a qualified healthcare professional.
Dr. Alice Rudd
Cofounder · Skin Science · MBBS Monash University
Alice is a cofounder of Stella, where she leads skin science. She trained at Monash University and practised in clinical dermatology before co-founding Stella to develop the metrics framework that underlies the app. She also runs Skindepth, a Melbourne-based dermatology practice.
Joanne Wismeyer
Cofounder · Member Experience
Joanne Wismeyer is a registered nurse and cofounder of Stella, where she leads member experience. She works directly with dermal clinicians and skin therapists across Australia.
